Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Duke Univ Med Ctr
mi
from
Durham, NC
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Moses Cone Health
mi
from
Greensboro, NC
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Moses Cone Health
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
University of Oklahoma Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Lehigh Valley Health Network
mi
from
Allentown, PA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Erlanger Hospital
mi
from
Chattanooga, TN
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Erlanger Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Memorial Hospital
mi
from
Chattanooga, TN
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Memorial Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Baylor University
mi
from
Dallas, TX
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Baylor University
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
U.S. Army Military Medical Center
mi
from
San Antonio, TX
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
U.S. Army Military Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Inova Fairfax Hospital
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
VCU Medical Center
mi
from
Richmond, VA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
VCU Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Pulmonary Associates of Mobile, P.C.
mi
from
Mobile, AL
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Pulmonary Associates of Mobile, P.C.
mi
from
Mobile, AL
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Mayo Clinic
mi
from
Phoenix, AZ
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Mayo Clinic
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Loma Linda University Medical Center
mi
from
Loma Linda, CA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Loma Linda University Medical Center
mi
from
Loma Linda, CA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Keck Hospital of USC
mi
from
Los Angeles, CA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Keck Hospital of USC
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Los Angeles County/University of Southern California Medical Center
mi
from
Los Angeles, CA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Los Angeles County/University of Southern California Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
University of California, Irvine Medical Center
mi
from
Orange, CA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Emory University
mi
from
Atlanta, GA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
University of Louisville
mi
from
Louisville, KY
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Henry Ford Hospital
mi
from
Detroit, MI
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Montefiore Medical Center-Weiler Division
mi
from
Bronx, NY
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Duke Regional Hospital
mi
from
Durham, NC
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Duke Regional Hospital
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Wesley Long Hospital
mi
from
Greensboro, NC
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Wesley Long Hospital
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
University of Cincinnati Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Cleveland Clinic - Fairview Hospital
mi
from
Cleveland, OH
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Cleveland Clinic - Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Oregon Health and Sciences University
mi
from
Portland, OR
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Oregon Health and Sciences University
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Geisinger Medical Center
mi
from
Danville, PA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Penn Presbyterian Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
John Peter Smith Hospital - JPS Health Network
mi
from
Fort Worth, TX
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
John Peter Smith Hospital - JPS Health Network
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
St Paul Regions Hospital
mi
from
Saint Paul, MN
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
St Paul Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated:  2/27/2018
Saint Louis University
mi
from
Saint Louis, MO
A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension
A Phase 3, Placebo-Controlled, Randomized, Double-Blind, Multi-Center Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension (CRH)
Status: Enrolling
Updated: 2/27/2018
Saint Louis University
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential
Status: Enrolling
Updated:  2/27/2018
UCIMC
mi
from
Orange, CA
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential
Status: Enrolling
Updated: 2/27/2018
UCIMC
mi
from
Orange, CA
Click here to add this to my saved trials
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS
Status: Enrolling
Updated:  2/27/2018
Rhode Island Hospital
mi
from
Providence, RI
The Ward Study for SeptiCyte® Lab to Distinguish Between Infection-positive and Infection-negative SIRS
To Assess the Performance of SeptiCyte® Lab to Diagnose Patients Identified as Suspected of Sepsis in General Medical and Surgical Wards With Infection-positive From Infection-negative SIRS
Status: Enrolling
Updated: 2/27/2018
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 404
mi
from
Phoenix, AZ
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 404
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 412
mi
from
Gainesville, FL
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 412
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 368
mi
from
Tampa, FL
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 368
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 03
mi
from
Lincoln, NE
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 03
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 16024
mi
from
Winston-Salem, NC
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 16024
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 413
mi
from
Seattle, WA
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 413
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated:  2/27/2018
Study Site 402
mi
from
Washington,
Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn Injury
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Status: Enrolling
Updated: 2/27/2018
Study Site 402
mi
from
Washington,
Click here to add this to my saved trials
Evaluation of Non-Invasive Hemoglobin in Trauma Patients
Evaluation of Non-Invasive Hemoglobin in Trauma Patients Using FDA-Cleared Masimo Pulse CO-Oximeter
Status: Enrolling
Updated:  2/27/2018
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Evaluation of Non-Invasive Hemoglobin in Trauma Patients
Evaluation of Non-Invasive Hemoglobin in Trauma Patients Using FDA-Cleared Masimo Pulse CO-Oximeter
Status: Enrolling
Updated: 2/27/2018
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
Investigating the Histopathological and Clinical Significance of Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
Status: Enrolling
Updated:  2/28/2018
Vanderbilt University
mi
from
Nashville, TN
Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
Investigating the Histopathological and Clinical Significance of Critical Illness Myopathy as a Cause of Debilitating ICU-Acquired Weakness
Status: Enrolling
Updated: 2/28/2018
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
Status: Enrolling
Updated:  2/28/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
Randomized Controlled Trial Comparing Low Dose and High Dose Steroids in Patients Undergoing Colorectal Surgery
Status: Enrolling
Updated: 2/28/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Alabama At Birmingham
mi
from
Birmingham, AL
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Alabama At Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
National Institute Of Transplantation
mi
from
Los Angeles, CA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
National Institute Of Transplantation
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
UCLA Medical Center
mi
from
Los Angeles, CA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
UCLA Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials